At the opening public session of the Instand-NGS4P Consortium Meeting, Ivo Gut (CNAG-CRG, Spain) and Sir Mark Caulfield (Genomics England) gave a
At the webinar on the Tendering Process, which was held on the 28th of April and was attended by up to 94
CEN/TS 17981-1:2023, In vitro diagnostic Next Generation Sequencing (NGS) workflows — Part 1: Human DNA examination CEN/TS 17981-2:2023, In vitro diagnostic Next Generation Sequencing (NGS) workflows — Part 2: Human RNA examination These 2 CEN/TS documents, developed by CEN/TC 140 WG3 in the context of the Instand-NGS4P project, cover all the steps needed to obtain successful and reliable sequence
High-level Conference: Tackling the implementation gap for the uptake of NGS and advanced molecular diagnostics into healthcare systems: The Role of Pathology and Medical Laboratories Organised as an ECP satellite event by the European Alliance for Personalized Medicine, this conference will present and discuss ways to improve patients´ benefits from advanced molecular diagnostics including NGS.
We are pleased to announce that of the ten Contractors that successfully completed Phase 2, eight have now been awarded Specific Contracts for Phase 3 to complete testing and integration of the innovative NGS workflows. Phase 3 commenced in April 2024 and will end in May 2025. Further details can be found under Phase 3
The Instand NGS4P project consortium and Contractors will meet in Graz on the 9th of April 2024 to present the project and the developed Solutions at a public meeting. Two keynote speakers, Jean-Yves Blay (from Instand-NGS4P Partner CLB) and Matthias Schwab (IKP) will give talks on the challenges of precision medicine of cancer and on
The canSERV Consortium announces its first Challenge-Call on "Advancing Personalised Oncology".Cancer Researchers in, and outside the EU are invited to apply for free access to cutting-edge transnational services with an indicative overall budget of EUR 500,000. The aim of this call is to accelerate knowledge gain in personalised oncology with specific emphasis on multi-level data-based
This year's meeting of the Instand NGS4P project consortium and contractors was held in Vienna, Austria, as a hybrid meeting combining both face-to-face and online formats. The two-day event provided a valuable platform for contractors to present their innovative prototypes to consortium members present from across Europe.In addition, the clinical project partners also had the
Instand-NGS4P Beneficiary, OECI - the Organisation of European Cancer Institutes - has dedicated an entire Newsletter to the Instand-NGS4P project. The Newsletter describes the aims of the project, and progress made to date. This is an important dissemination tool, with the OECI Audience comprising 1300 contacts including: OECI Membership; Cancer Organisations and & relevant cancer
This workshop addresses the key issues facing genomic research such as ethical and legal issues, privacy and data protection, data standardisation and implementation of standardised sample workflows. For further information on this event organised jointly by BBMRI-ERIC and EASI-Genomics, please visit Workshop on Implementing Genomic Research Projects | EASI-Genomics
We are delighted to announce that 11 of the 14 Contractors who completed Phase 1 have been selected to enter Phase 2 and were awarded contracts on the 15th of November 2022 for development of prototypes based on their Solution Designs. Further details including the project abstracts can be found under Phase 2 – Prototype
Analysis carried out by Instand-NGS4P´s WP7 of existing gaps in current standardization led to the proposal of 2 new Work Items for development in partnership with CEN/TC 140 “In vitro diagnostic medical devices” WG3 “Quality Management in the Medical Laboratory”:00140151 - prCEN/TS XXX In vitro diagnostic Next Generation Sequencing (NGS) workflows - Part 1: Human